LDL-Bound PCSK9 Has a Slower Clearance Kinetic and Higher Use for HSPGs Than Free-PCSK9—Brief Report
Arteriosclerosis, Thrombosis, and Vascular Biology · 2025
DOI: 10.1161/atvbaha.124.322334 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2025. Verfasst von Silvia Cecilia Pacheco-Velázquez und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland (S.C.P.-V., C.O., J.H., P.A.M., J.M.,…. Hauptthemen laut MEDLINE: Proprotein Convertase 9, Liver, Lipoproteins, LDL, Heparan Sulfate Proteoglycans. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NIGMS NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Hepatic heparan sulfate proteoglycans (HSPGs) accelerate the clearance of PCSK9 (proprotein convertase subtilisin/kexin type 9). We tested the hypothesis that free- and LDL (low-density lipoprotein)–bound PCSK9 forms have different HSPG-mediated clearance kinetics. METHODS: Metabolic and turnover studies were performed after administration of free- and LDL-bound PCSK9 to 2 HSPG knockout mouse models: (1) Global knockout of syndecan-1 ( Sdc1 −/ − ), an HSPG involved in hepatic triglyceride clearance; and (2) hepatocyte-specific knockout of heparan sulfate N-deacetylase/N-sulfotransferase (AlbCre + Ndst1 f/f ). RESULTS: The clearance of both free- and LDL-bound PCSK9 followed a 2-phase decay behavior comprising a fast and a slow phase. The more notorious effect of HSPG deletion was on the slow phase: the clearance of free-PCSK9 was faster in Sdc1 −/ − mice (t 1/2,slow [half-life on the slow phase] 13.5±1.5 minutes; P =0.0305) than in wild-type (t 1/2,slow 28.8±4.2 minutes) and AlbCre + Ndst1 f/f mice (t 1/2,slow 32.7±4.9 minutes). The clearance of LDL-bound PCSK9 was slower yet not statistically significant in Sdc1 −/ − mice (t 1/2,slow 111.2±21.6 minutes) than in wild-type (t 1/2,slow 52±6.4 minutes) and AlbCre + Ndst1 f/f mice (t 1/2,slow 39.55±2.96 minutes). However, the area under the curve showed a delayed clearance of LDL-bound PCSK9 in Sdc1 −/ − mice (44 576±2435 min×ng, P =0.004) but not in AlbCre + Ndst1 f/f (34 738±3721 min×ng, P =0.578) mice compared with wild-type (30 865±1907 min×ng). Hepatic Ndst1 -deficiency did not alter hepatic PCSK9 or LDLR (LDL receptor) expression. CONCLUSIONS: The clearance rate of plasma LDL-bound PCSK9 is slower than the clearance rate of its free form. The HSPG syndecan-1 modestly contributes to PCSK9 clearance through an LDLR-independent pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland (S.C.P.-V., C.O., J.H., P.A.M., J.M., H.T., S.F., N.P.).
- Division of Endocrinology and Metabolism, Department of Medicine (B.R., C.C., P.L.S.M.G.), University of California San Diego, La Jolla.
- Department of Biochemistry and Physiology, School of Pharmacy and Food Sciences, Universitat de Barcelona, Spain (E.L.-A.).
- Department of Chemistry and Biochemistry (R.N.P., C.C., K.G.), University of California San Diego, La Jolla.
- Glycobiology Research and Training Center (K.G., P.L.S.M.G.), University of California San Diego, La Jolla.
- Division of Microbiology & Immunology, Department of Pathology, University of Utah School of Medicine, Salt Lake City (P.L.S.M.G.).
ORCID-Profile: Silvia Cecilia Pacheco-Velázquez, Carlota Oleaga, Bastian Ramms, Joshua Hay, Paul A Mueller, Ester López-Aguilar, Joshua Miles, Kamil Godula, Hagai Tavori, Philip L S M Gordts, Sergio Fazio, Nathalie Pamir
Förderung
- NICHD NIH HHS
- NIGMS NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Pacheco-Velázquez, S. C., Oleaga, C., Ramms, B., Hay, J., Mueller, P. A., López-Aguilar, E., Miles, J., Porell, R. N., Cheng, C., Godula, K., Tavori, H., Gordts, P. L. S. M., Fazio, S., & Pamir, N. (2025). LDL-Bound PCSK9 Has a Slower Clearance Kinetic and Higher Use for HSPGs Than Free-PCSK9—Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.124.322334
Vancouver
Pacheco-Velázquez SC, Oleaga C, Ramms B, Hay J, Mueller PA, López-Aguilar E, et al. LDL-Bound PCSK9 Has a Slower Clearance Kinetic and Higher Use for HSPGs Than Free-PCSK9—Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology. 2025. doi:10.1161/atvbaha.124.322334
BibTeX
@article{PachecoVelzquez2025,
author = {Pacheco-Velázquez, Silvia Cecilia and Oleaga, Carlota and Ramms, Bastian and Hay, Joshua and Mueller, Paul A and López-Aguilar, Ester and Miles, Joshua and Porell, Ryan N and Cheng, Chelsea and Godula, Kamil and Tavori, Hagai and Gordts, Philip L S M and Fazio, Sergio and Pamir, Nathalie},
title = {LDL-Bound PCSK9 Has a Slower Clearance Kinetic and Higher Use for HSPGs Than Free-PCSK9—Brief Report},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2025},
doi = {10.1161/atvbaha.124.322334}
}
EUVIMED